Skip to content

Rosacea Prevalence in General Population - Pilot Study

Rosacea Prevalence in General Population - Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02292836
Enrollment
120
Registered
2014-11-17
Start date
2012-08-31
Completion date
2013-02-28
Last updated
2014-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

The purpose of this study is to test and refine, a subject questionnaire aimed to be used in a general population rosacea prevalence study.

Detailed description

The study will test the subject questionnaire aimed to be used in a full general population prevalence study to screen potential subjects with rosacea. Questionnaire will be self-administrated to Dermatology outpatients. Testing will be performed at the practice of 2 Dermatologists experts in rosacea who will evaluate subjects' answers and propose fine-tuning of the questionnaire content, if needed.

Interventions

OTHERQuestionnaire testing

Questionnaire testing on rosacea and non-rosacea dermatology outpatients

Sponsors

Galderma R&D
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Male or Female aged between 18 (or locally accepted majority) and 65 years old both included. * Subject visiting one of the study dermatology practices for daily care/routine dermatology consultation. * Subject have to read and sign the approved Informed Consent form prior to any participation in the study, * Subject willing and capable of cooperating to the extend and degree required by the protocol

Design outcomes

Primary

MeasureTime frameDescription
sensitivity and specificity of questionsDay 1sensitivity and specificity of each questionnaire key items by comparing subject answers and investigator assessments, as follows: Sensitivity= True Positive/(True Positive+False Negative) Specificity= True Negative/ (False Positive+True Negative)

Countries

Canada, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026